Agios Pharmaceuticals AGIO Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Agios Pharmaceuticals's shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Agios Pharmaceuticals's shares (diluted)?
- Agios Pharmaceuticals (AGIO) reported shares (diluted) of 58.8M in Q1 2026.
- How has Agios Pharmaceuticals's shares (diluted) changed year-over-year?
- Agios Pharmaceuticals's shares (diluted) increased by 2.3% year-over-year, from 57.5M to 58.8M.
- What is the long-term trend for Agios Pharmaceuticals's shares (diluted)?
- Over 4 years (2021 to 2025), Agios Pharmaceuticals's shares (diluted) has grown at a -1.7% compound annual growth rate (CAGR), from 248.1M to 231.5M.
- What does shares (diluted) mean?
- The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.